Information Provided By:
Fly News Breaks for March 25, 2015
MDVN
Mar 25, 2015 | 07:39 EDT
Brean Capital raised its price target on Medivation to $142 from $125 following the presentation of additional Phase 2 TERRAIN trial data in metastatic castration-resistant prostate cancer and final OS data from the Phase 3 PREVAIL trial in chemo-naive mCRPC. The firm remains optimistic by consistent and positive data and reiterated its Buy rating on Medivation shares.
News For MDVN From the Last 2 Days
There are no results for your query MDVN